The Petrovax strategy is historically based on the development of original pharmaceutical products. The Company has its own state-of-the-art R&D center and invests in R&D projects aimed at the development of new products annually.
The Company holds more than 20 patents for molecules and pharmaceutical manufacturing technologies.
The R&D center allows managing the molecule inception and product lifecycle from the idea to implementation in medical practice. We involve leading Russian and foreign specialized research institutions in our ad hoc studies.
Innovative search for promising candidate molecules with subsequent assessment of their safety and specific activity.
Exploring developmental mechanisms of action of the disease processes.
Exploring the safety and efficacy profile of candidate drugs in preclinical studies.
Development of quality control methods and manufacturing technology.
Planning and conducting clinical registration studies.
Implementing technological processes, upgrading and optimization of current processes; production scaling.
In 2018, Grippol® Quadrivalent, the first Russian 4-valent influenza vaccine, was launched to the market.
Petrovax has a certified state-of-the-art vivarium with four types of laboratory animals. It is used for preclinical studies of original drug products to assess drug efficacy and safety and provide services to partnership organizations. Vivarium temperature, air humidity and light conditions are maintained at the level required to keep SPF mice and rats as well as conventional rabbits and guinea pigs. Preclinical data from in-house studies form the basis for marketing authorization applications for the drugs developed by Petrovax. The Company’s R&D divisions have passed ISO:9001 quality audits. The Company is ready to conduct studies on a contractual basis.